Iron parameters in patients with end-stage renal disease receiving lanthanum carbonate or other non-iron-based phosphate binders: Results from a phase 3, randomized open-label study:

摘要

Objectives:The recent availability of iron-based phosphate binders has raised some concerns about iron overload in patients with end-stage renal disease. This study evaluated iron parameters in patients with end-stage renal disease receiving lanthanum carbonate or other non-iron-based phosphate binders.Methods:This analysis used 2-year follow-up data from an open-label, multicentre, randomized, active-controlled, parallel-group, phase 3 trial of lanthanum carbonate (SPD405-307). After a washout period, if patients’ serum phosphate levels exceeded 5.9?mg/dL, they were randomized 1:1 to receive lanthanum carbonate (375–3000?mg/day) or non-iron-based standard therapy during a 6-week dose titration period. Patients achieving control of serum phosphate levels (?5.9?mg/dL) received maintenance therapy with lanthanum carbonate or standard therapy for up to 24?months.Results:No clinically relevant changes in mean (standard deviation) iron parameters between the treatment groups (lanthanum carbonate, n?=?682; stan...